J&J drops Addex’s epilepsy treatment after flunking in Phase II
A Phase II trial with Johnson and Johnson (J&J) and Addex’s epilepsy drug had failed to meet the primary endpoint in April.
A Phase II trial with Johnson and Johnson (J&J) and Addex’s epilepsy drug had failed to meet the primary endpoint in April.
What's Your Reaction?
